Profile data is unavailable for this security.
About the company
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.
- Revenue in USD (TTM)1.82m
- Net income in USD-101.39m
- Incorporated2005
- Employees87.00
- LocationLyra Therapeutics Inc480 Arsenal WayWATERTOWN 02472United StatesUSA
- Phone+1 (617) 373-4600
- Fax+1 (302) 655-5049
- Websitehttps://lyratherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspira Women's Health Inc | 8.92m | -15.95m | 13.04m | 64.00 | -- | -- | -- | 1.46 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Alterola Biotech Inc | 0.00 | -2.06m | 13.14m | 1.00 | -- | -- | -- | -- | -0.0017 | -0.0017 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -32.46 | -- | -46.53 | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | -- | -- | -14.64 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -6.24m | 13.21m | 4.00 | -- | 3.31 | -- | -- | -5.88 | -5.88 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -138.35 | -- | -173.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.52m | 2.00 | 3.48 | 0.2847 | 3.01 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Cingulate Inc | 0.00 | -19.10m | 13.70m | 13.00 | -- | 1.14 | -- | -- | -141.60 | -141.60 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -368.85 | -- | -- | -- | -- | -- | -- | -- | -- | -47.38 | 0.0042 | -- | -- | -- | -33.14 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -6.93m | 13.96m | 16.00 | -- | 4.87 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Aprea Therapeutics Inc | 1.28m | -12.93m | 14.13m | 7.00 | -- | 0.5526 | -- | 11.08 | -3.03 | -3.03 | 0.2898 | 4.95 | 0.0435 | -- | -- | 182,241.40 | -44.09 | -68.66 | -50.11 | -77.19 | -- | -- | -1,013.41 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Lyra Therapeutics Inc | 1.82m | -101.39m | 14.31m | 87.00 | -- | 0.4619 | -- | 7.86 | -1.61 | -1.61 | 0.0294 | 0.4733 | 0.0165 | -- | -- | 20,681.82 | -92.07 | -58.01 | -108.51 | -68.69 | -- | -- | -5,570.88 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Imunon Inc | 0.00 | -18.08m | 14.40m | 33.00 | -- | 2.51 | -- | -- | -1.92 | -1.92 | 0.00 | 0.398 | 0.00 | -- | -- | 0.00 | -94.15 | -50.18 | -132.90 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.02m | 14.61m | 3.00 | -- | 3.53 | -- | -- | -0.0175 | -0.0175 | 0.00 | 0.024 | 0.00 | -- | -- | 0.00 | -34.83 | 27.48 | -34.99 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 14.95m | 4.00 | -- | -- | -- | 19,926.77 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Apollomics Inc | 0.00 | -57.11m | 15.62m | 45.00 | -- | 0.7505 | -- | -- | -0.568 | -0.568 | 0.00 | 0.1892 | 0.00 | -- | -- | 0.00 | -107.81 | -- | -144.29 | -- | -- | -- | -- | -- | -- | -- | 0.185 | -- | -- | -- | 28.33 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 278.00k | -15.21m | 15.84m | 49.00 | -- | 12.26 | -- | 56.96 | -36.98 | -36.98 | 0.1048 | 0.2316 | 0.0174 | -- | 0.3493 | 5,673.47 | -95.08 | -100.11 | -126.11 | -131.65 | -- | -- | -5,469.42 | -131,560.30 | -- | -- | 0.8933 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
Data as of Oct 08 2024. Currency figures normalised to Lyra Therapeutics Inc's reporting currency: US Dollar USD
46.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Mar 2024 | 12.76m | 20.93% |
| Citadel Advisors LLCas of 03 Apr 2024 | 2.85m | 4.67% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 2.82m | 4.63% |
| Point72 Asset Management LPas of 31 Mar 2024 | 2.75m | 4.51% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.47m | 2.41% |
| Pura Vida Investments LLCas of 31 Mar 2024 | 1.41m | 2.32% |
| Ikarian Capital LLCas of 31 Mar 2024 | 1.06m | 1.73% |
| Rosalind Advisors, Inc.as of 30 Jun 2024 | 1.03m | 1.70% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 985.63k | 1.62% |
| Tri Locum Partners LPas of 31 Mar 2024 | 978.79k | 1.61% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
